A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
Phase 3
2,600
about 3.7 years
18+
4 sites in AL, CA, MO +1
About this study
Researchers are testing whether Finerenone, a treatment, is effective and safe compared to placebo in people with heart failure who cannot take steroidal mineralocorticoid receptor antagonists (sMRA). The trial will last 1349 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Finerenone
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
finerenone
oral (Oral Tablet)
Primary: Number of adverse events leading to discontinuation of study drug., Number of serious adverse events
Secondary: Change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) from baseline to Month 6.
Cardiology / Heart